• Agilent Technologies (Santa Clara, California) has introduced the latest version of its Agilent DNA microarray scanner, using SureScan high resolution technology to deliver high resolution and rapid scan times for current and next-generation microarrays. The new scanner offers resolutions of 10 microns, 5 microns, 3 microns and 2 microns, and the instrument can scan a 244,000 feature microarray at the maximum resolution in about 20 minutes. Agilent Technologies is a measurement company and a technology leader in communications, electronics, life sciences and chemical analysis.

• Biopure (Cambridge, Massachusetts) said that the results from its Phase III orthopedic trial (HEM-115) have been published in the June issue of the Journal of Trauma. The paper is titled "HBOC-201 as an Alternative to Blood Transfusion: Efficacy and Safety Evaluation in a Multicenter Phase III Trial in Elective Orthopedic Surgery." The paper's authors concluded that HBOC-201 eliminated the need for transfusion in the majority of patients. Patients less than 80 years of age with moderate clinical needs safely avoided transfusions when treated with up to 10 units of HBOC-201. The intent-to-treat analysis was unfavorable, with the crossover group (HBOC-201 to PRBC) being identified as the primary basis for the difference. The analytical methodology used identified that the crossover patients had a greater need for an oxygen carrier, likely related to patient age, volume overload and under-treatment. Biopure makes oxygen therapeutics.

• biospace med (Atlanta) reported that New Jersey Spine Group (Eatontown, New Jersey) is the first healthcare facility in the U.S. to install the company's EOS X-ray imager–an ultra-low-dose x-ray technology. EOS can capture head-to-toe images of patients in a standing, weight-bearing position with a reduction in radiation dose–up to 10 times less than a conventional x-ray and up to 1000 times less than a CTscan. biospace med is a total solution in orthopedic imaging company.

• Cardiac Science (Bothell, Washington) said it has completed certification for its HeartCentrix ECG informatics software with the Allscripts Electronic Health Record (EHR). The connectivity between Cardiac Science's equipment and the Allscripts EHR will help physicians streamline the diagnostic cardiology workflow in their offices, eliminate a source of data transcription errors, and provide a unified view of patient diagnostic data. With HeartCentrix ECG informatics, physicians will have immediate access to view or edit a patient's test results electronically and later retrieve the data from the Electronic Health Record. Cardiac Science makes resuscitation, rehabilitation and informatics products.

The registry arm of a clinical study measuring the effectiveness of Cook Medical's (Spencer, Indiana) Zilver PTX drug-eluting peripheral stent (DES) in treating peripheral arterial disease (PAD) has yielded positive interim results. "Cook's registry study and randomized trial are the first to use a paclitaxel-coated stent in the treatment of arterial blockages outside the heart," said Michael Dake, MD, professor of radiology, internal medicine and surgery at the University of Virginia Health System, and the trial's principal investigator. "They are designed to evaluate the safety and effectiveness of DES technology vs. percutaneous transluminal angioplasty, and our initial findings in the registry arm give us every reason to believe that Zilver PTX has the integrity, safety and durability needed to successfully address many of the well-known limitations of angioplasty alone for management of PAD." Cook Medical specializes in interventional medicine products.